Humira's resilience in the face of biosimilar competition

Biosimilares/General | Posted 30/07/2024 post-comment0 Post your comment

AbbVie’s Humira (adalimumab) has retained more than 80% of patients in the last year (Q3/2023 to Q2/2024), despite the availability of nine lower-priced rival products available in the US. This raises questions among drug pricing experts and analysts about whether the market for prescription biosimilars can survive in its current form.

20 AA010933

Humira, priced at nearly US$7,000 a month in the US, is the first leading drug to face competition from a range of 10 biosimilars of AbbVie's blockbuster arthritis drug. Six of these biosimilars come in the more popular high-concentration version, and all are citrate-free, see Table 1. The three largest pharmacy benefit managers (PBMs) have included two to three of these biosimilars on their lists of covered drugs for 2024.

Adalimumab is a human monoclonal antibody treats autoimmune diseases including rheumatoid arthritis, juvenile idiopathic and psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis and ulcerative colitis [1]. 

Table 1:  Biosimilar adalimumab launched in the US*
Product name Company  Launched in the US Interchangeable High concentration Citrate free
Abrilada (adalimumab-afzb) Pfizer Oct 2023 Yes No Yes
Amjevita (adalimumab-atto) Amgen Jan 2023 No Yes Yes
Cyltezo (adalimumab-adbm) Boehringer Ingelheim Jul 2023 Yes No Yes
Hadlima (adalimumab-bwwd) Organon/Samsung Bioepis Jul 2023 No Yes Yes
Hulio (adalimumab-fkjp) Biocon Jul 2023 No No Yes
Hyrimoz (adalimumab-adaz) Sandoz Jul 2023 Yes Yes Yes
Idacio (adalimumab-aacf) Fresenius Kabi Jul 2023 No No Yes
Simlandi (adalimumab-ryvk)  Alvotech/Teva May 2024 Yes Yes Yes
Yuflyma (adalimumab-aaty) Celltrion Jul 2023 No No Yes
Yusimry (adalimumab-aqvh)  Coherus Biosciences Jul 2023 No No Yes
*Data updated 30 July 2024.
Note: High-concentration versions of Hyrimoz, Hadlima and Yuflyma were available on launch, but those versions of Amjevita and Cyltezo only became available in 2024. The Cost Plus Drug Company started offering Yusimry at US$569.27 plus dispensing and shipping fees in July 2024.

 

The first adalimumab biosimilar, Amgen’s Amjevita, was approved in the US in 2016 [2], and since then, eight more have been approved. However, they were only launched in 2023 due to patent expiry extensions and agreements between AbbVie and the biosimilars companies [3, 4].

Since its launch, the uptake of the products has been slow, despite being offered at discounted prices through PBMs [5]. From Q3/2023 to Q2/2024, AbbVie filled a total of more than 3,316,804 prescriptions for Humira, while all its competitors combined filled just over 131,793 prescriptions of their biosimilars. The data exclude sales of Teva/Alvotech’s Humira biosimilar, Simlandi, which became available in the US only in May 2024.

Despite the sharply discounted prices of biosimilars, CVS Caremark did not remove Humira from its list of covered drugs [6] until April 2024. This marked the beginning of an increase in the uptake of adalimumab biosimilars. Starting in June 2024, CVS began covering a Sandoz biosimilar and a co-branded Humira, both through its new Cordavis pharmaceutical unit.

Stacie Dusetzina, a health policy professor at Vanderbilt University, has noted that regulatory reform is needed so patients can more easily access biosimilars and attract rival drugmakers to develop them. ‘It's not clear to me there's any incentive at all for companies to spend their time and money creating biosimilars. And if no one will, then the price of the brand drug would never come down,’ she said.

In addition, a recent article by Dr Joshua Cohen discusses the challenges facing the adoption of biosimilars in the US, particularly focusing on Medicare beneficiaries’ access to these lower-cost alternatives to brand-name biologicals like Humira [7].

Related articles
FDA approves interchangeable adalimumab biosimilar Simlandi

The latest biosimilars agreements

LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Actualización de la guía de biosimilares intercambiables de la FDA sobre el enfoque revisado para los estudios de cambio

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

FORO LATINOAMERICANO
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Actualización de la guía de biosimilares intercambiables de la FDA sobre el enfoque revisado para los estudios de cambio

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

 

References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of adalimumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jul 30]. Available from: www.gabionline.net/biosimilars/general/biosimilars-of-adalimumab
2. GaBI Online - Generics and Biosimilars Initiative. FDA approval for Amgen’s adalimumab biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jul 30]. Available from: www.gabionline.net/biosimilars/news/FDA-approval-for-Amgen-s-adalimumab-biosimilar
3. GaBI Online - Generics and Biosimilars Initiative. Amgen’s adalimumab biosimilar will only be launched in US in 2023 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jul 30]. Available from: www.gabionline.net/biosimilars/news/Amgen-s-adalimumab-biosimilar-will-only-be-launched-in-US-in-2023
4. GaBI Online - Generics and Biosimilars Initiative. AbbVie and Samsung Bioepis reach patent deal over Humira biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jul 30]. Available from: www.gabionline.net/biosimilars/general/AbbVie-and-Samsung-Bioepis-reach-patent-deal-over-Humira-biosimilar
5. GaBI Online - Generics and Biosimilars Initiative. US PBMs add multiple Humira biosimilars to formularies [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International [cited 2024 Jul 30]. Available from: www.gabionline.net/biosimilars/general/us-pbms-add-multiple-humira-biosimilars-to-formularies
6. GaBI Online - Generics and Biosimilars Initiative. CVS Caremark removes Humira in the US and Sandoz launches Hyrimoz in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International [cited 2024 Jul 30]. Available from: www.gabionline.net/biosimilars/general/cvs-caremark-removes-humira-in-the-us-and-sandoz-launches-hyrimoz-in-europe
7. GaBI Online - Generics and Biosimilars Initiative. Addressing the persistent gap in Medicare access to Humira biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International [cited 2024 Jul 30]. Available from: www.gabionline.net/biosimilars/general/addressing-the-persistent-gap-in-medicare-access-to-humira-biosimilars

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2024 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010